Changes in Beneficial Ownership · 4
Neuronetics, Inc.
STIMNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-11-16
- Issuer
- Neuronetics, Inc.
- Issuer CIK
- 0001227636
- Trading symbol
- STIM
Reporting owner 1
- Name
- MUIR GLENN P
- Reporting owner CIK
- 0001181190
- Relationship
- Director
- Address
- C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN, PA, 19355
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-11-16 | A · Form 4 | 175,000 | A | 1.31[F1] | 576,816 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.25 to $1.385. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
Signature 1
- Signed
- /s/ Francis Brown, as Attorney-in-Fact
- Date
- 2026-11-18
Company context
Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (“TMS”) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for major depressive disorder (“MDD”) in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant. 1